CM346, also known as Obenoxazine, is primarily utilized in the field of medical research and therapeutic applications. It is being investigated for its potential neuroprotective properties, particularly in the context of neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound has shown promise in preclinical studies for its ability to mitigate neuronal damage and improve cognitive functions. Researchers are exploring its efficacy in reducing oxidative stress and inflammation in neural tissues, which are key factors in the progression of these diseases. Additionally, CM346 is being studied for its role in enhancing synaptic plasticity, which is crucial for memory and learning processes. Its application extends to the development of novel therapeutic agents aimed at slowing down or halting the degenerative processes in the brain. Clinical trials are underway to further evaluate its safety and effectiveness in human subjects, with the hope of providing a new treatment option for patients suffering from debilitating neurological conditions.